Eagle Pharmaceuticals (EGRX) Tops Q4 EPS by 28c

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $1.11, $0.28 better than the analyst estimate of $0.83. Revenue for the quarter came in at $60.7 million versus the consensus estimate of $64.26 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• American Eagle Outfitters names new CFO, reaffirms 2026 guidance
• Bassett Furniture Industries (BSET) Tops Q2 EPS by 1c, Misses on Revenue